Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
This life-threatening pediatric disease can cause sideroblastic anemia, metabolic crisis, and bone marrow failure.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Exploring treatment sequencing, prior therapy impact, and targeted approaches in lower-risk myelodysplastic syndromes.
ELEMENT-MDS trial tests luspatercept vs epoetin alfa for anemia in ESA-naive, lower-risk MDS without transfusion need.
Our expert roundtable reacts to data presented at ASCO 2025 on real-world use of the agent in this setting.
Experts discuss what data do clinicians need in order to optimize their first-line use of this agent for low-risk MDS.
The document reflects the FDA’s recommendations for drug development, clinical trial designs, efficacy end points, and ...
Our expert panel reacts to the updated efficacy and safety data for luspatercept presented at ASCO 2025.
Panelists discuss how these biomarkers factor into their therapy choices and the impact of new data from ASCO 2025.
End Point Success Varies in a Phase 3 Trial of Luspatercept Plus JAK Inhibitor Therapy for MF Anemia
The combination did not meet the primary end point for RBC transfusion independence but still markedly improved anemia.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
No new safety signals were observed in this phase 3 trial which compared the combination with placebo plus azacitidine.
Bexmarilimab shows promising responses in high-risk MDS, with up to 85% ORR in the BEXMAB phase 2 study.
The comparative results from a first-of-its-kind healthcare claims database study support this conclusion.
Luspatercept shows longer survival and transfusion independence in ESA-naïve lower-risk MDS, COMMANDS trial.
Dr. Idoroenyi Amanam explains why luspatercept offers new hope for patients with low-risk myelodysplastic syndromes.
SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR-NK cell therapy, is currently being evaluated in a phase 1 trial.
The phase 1/2 study's safety and efficacy data on bexmarilimab plus azacitidine for high-risk MDS are promising.
Azacitidine plus valproic acid is a safe and feasible maintenance regimen for patients with high-risk AML and MDS after HSCT.
Frontline luspatercept demonstrates superior efficacy compared with ESAs in patients with lower-risk MDS.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.